Insulin Resistance & Type 2 Diabetes — USA & UK 1975–2022

Insulin Resistance & Type 2 Diabetes

Prevalence trajectories in the USA and United Kingdom, 1975–2022. Type 2 diabetes is the most direct downstream consequence of insulin resistance — the right axis shows diagnosed T2DM, representing the late-stage outcome of the same metabolic process measured on the left axis.

Why the two curves don't track each other exactly — even when the correlation is very high:

The solid line shows the percentage of adults with insulin resistance across the entire population — everyone with measurable insulin resistance, regardless of what condition it causes them. Because insulin resistance is the upstream root cause of many different diseases — type 2 diabetes, fatty liver, cognitive decline, cardiovascular disease and more — this curve rises relatively gradually as it reflects a burden shared across all of those outcomes.

The dotted line shows the prevalence of the specific condition studied on this page — in this case, only the people for whom insulin resistance has expressed itself as that particular disease. This curve can rise more steeply because it captures decades of accumulated cases: someone may develop insulin resistance at 35 but not manifest this condition until their 50s, so even a modest early rise in insulin resistance translates into a much larger rise in diagnosed cases years later.

The r value (e.g. r = 0.97) is a correlation coefficient. It doesn't measure whether the two lines are the same height — it measures how consistently they move together over time. An r of 0.97 means that 97% of the rise in this condition over the past five decades is statistically explained by the parallel rise in insulin resistance.

What the r value tells you:
0.50–0.70 — Modest connection. The two trends are related but many other factors are involved.
0.70–0.90 — Strong connection. Insulin resistance is a major driver, alongside other contributing causes.
0.90 and above — Dominant connection. Insulin resistance accounts for the overwhelming majority of the trend. At this level, it is difficult to argue that other factors are primarily responsible. The values seen across these studies — consistently 0.90 to 0.97 — place insulin resistance firmly in this category for every condition shown.

United States

USA — Insulin Resistance vs T2DM

1975 – 2022  |  % of population
Insulin Resistance
T2DM Diagnosed
United Kingdom

UK — Insulin Resistance vs T2DM

1975 – 2022  |  % of population
Insulin Resistance
T2DM Diagnosed
r = 0.98
USA
IR ↔ T2DM
r = 0.97
UK
IR ↔ T2DM
+400%
USA T2DM rise
1975 – 2022
+350%
UK T2DM rise
1975 – 2022
The defining relationship: T2DM is the clinical end-stage of insulin resistance. HOMA-IR scores above approximately 2.5 indicate clinically significant insulin resistance; once beta-cell exhaustion follows, diagnosed T2DM results. The r values here (0.97–0.98) approach the maximum possible for ecological data, because these two measures are not merely correlated — they are sequential stages of the same physiological process. A HOMA-IR test will typically detect insulin resistance 10–20 years before T2DM diagnosis — the critical reversible window that conventional medicine largely misses.
Data sources
T2DM USA: CDC National Diabetes Statistics Report 1980–2022; NHANES 1999–2020; Geiss et al. JAMA 2014. Age-adjusted diagnosed diabetes prevalence: ~1.0% (1975) → 2.2% (1990) → 4.5% (2000) → 6.4% (2010) → 7.4% (2022). Undiagnosed cases add an estimated further 25%.
https://www.cdc.gov/diabetes/php/data-research/index.html
https://jamanetwork.com/journals/jama/fullarticle/1835948
T2DM UK: Diabetes UK State of the Nation reports 2010–2022; NHS Digital National Diabetes Audit 2003–2022; Health Survey England. UK prevalence: ~1.2% (1975) → 3.5% (2000) → 7.0% (2022). ~4.3 million diagnosed in UK 2022, ~90% T2DM.
https://www.diabetesuk.org/professionals/position-statements-reports/statistics/
https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit
Insulin Resistance USA: NHANES III 1988–94; NHANES 1999–2018 (Hirode & Wong, JAMA 2020); Frontiers meta-analysis 2025.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11601873/
https://pmc.ncbi.nlm.nih.gov/articles/PMC12411212/
Scroll to Top
MENU
For Radiant Health